Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations

Jordan, Karin; Sippel, Christoph; Schmoll, Hans‐Joachim

doi:10.1634/theoncologist.12-9-1143

Cited by 167 publications

(141 citation statements)

References 29 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…49,50 Another limiting factor of the use of this drug orally is the decreased bioavailability versus parenteral route, due to first-pass metabolism, in addition to the potential decrease in its absorption as a result of frequent episodes of vomiting caused by the treatment with cyclophosphamide. 31 Taking into account the concepts that guide the rational use of pharmaceuticals, including the reduction of treatment costs for both the patient and society, oral administration of mesna would have also the advantage of a likely decrease in expenses, due the lower bed occupancy time and less workload of the nursing team. 51 Still in this context, another possible disadvantage is the patient's non-compliance; thus, one cannot be sure that the patient has taken, or otherwise, the last dose of mesna PO.…”

Section: Fig 2 -Guidelinesmentioning

confidence: 99%

“…55 The second dose of mesna (20% of cyclophosphamide dose) is administered in the interval between 15 and 30 min after the administration of cyclophosphamide. 28 Nausea and vomiting are considered as common adverse reactions in chemotherapy, and this also occurs with cyclophosphamide 31 which, in turn, participates of many chemotherapeutic regimens. In this case, a routine has been proposed for the treatment of rheumatic diseases.…”

Section: Fig 2 -Guidelinesmentioning

confidence: 99%

See 1 more Smart Citation

Cyclophosphamide Administration Routine in Autoimmune Rheumatic Diseases: A Review

Teles

Souza

Лима³

et al. 2018

Nefrologiâ (St.-Peterbg.)

View full text Add to dashboard Cite

r e v b r a s r e u m a t o l . 2 0 1 7;5 7injetáveis. O trabalho objetivou a estruturação de uma rotina do uso de ciclofosfamida, bem como a criação de um documento de orientaç ões farmacoterapêuticas para o paciente. A rotina foi esquematizada em três fases, a pré-quimioterapia, a administração da ciclofosfamida e a pós-quimioterapia, que levaram em consideração os medicamentos que devem ser administrados antes e depois da ciclofosfamida para prevenção aos efeitos adversos, incluindo náusea e cistite hemorrágica. As reaç ões adversas podem alterar os exames laboratoriais e a rotina incluiu manejo clínico para alteração clínica dos leucócitos, das plaquetas, dos neutrófilos e do sódio incluindo o ajuste de dose de ciclofosfamida em caso de insuficiência renal. A ciclofosfamida é responsável por outras reaç ões adversas raras, mas sérias, como hepatotoxicidade, hiponatremia severa e falência cardíaca. Outras reaç ões adversas incluem perda de cabelo, amenorreia e menopausa. A rotina foi composta também por orientaç ões ao paciente pós-quimioterapia. A compatibilidade dos medicamentos injetáveis com o veículo foi descrita, bem como o tempo de estabilidade e o tempo de infusão.A rotina visou ao uso racional da ciclofosfamida e prevenir os efeitos adversos e os episódios de recidiva, os quais podem onerar o sistema de saúde.

show abstract

Section: Fig 2 -Guidelinesmentioning

confidence: 99%

Section: Fig 2 -Guidelinesmentioning

confidence: 99%

Cyclophosphamide Administration Routine in Autoimmune Rheumatic Diseases: A Review

Teles

Souza

Лима³

et al. 2018

Nefrologiâ (St.-Peterbg.)

View full text Add to dashboard Cite

show abstract

“…Antiemetic guidelines are published by several groups including MASCC, ASCO and NCCN [22]. The differences in the guidelines often relate to when they are updated and therefore encompass the latest literature.…”

Section: Guidelinesmentioning

confidence: 99%

Antiemetic research: future directions

Olver

Molassiotis

Aapro

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

Purpose and methods As a part of reviewing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines in Perugia in 2009, an expert group identified directions for future antiemetic research. Results and conclusions In future trials, the prediction of nausea and vomiting may combine algorithms based on observed prognostic factors relating to the patient and the anticancer therapy, the identification of the genes that code for receptors, and pharmacogenetic studies of the metabolism of drugs. Design issues for future trials include standardising the emetic stimulus across studies and finding the minimum tolerated effective dose and schedule of an antiemetic. Also control of delayed emesis is not independent of the control of acute emesis. The full range of side effects and the impact on global quality of life scores should be part of the routine assessment of an antiemetic. With current high rates of control of acute vomiting, future trials will need to consider new primary endpoints such as nausea, a complex symptom, where improvement is needed. Economic endpoints should be incorporated to ascertain the cost benefit of antiemetic prophylaxis, taking into account the impact of nausea on work capacity. New antiemetic drugs may be targeted at different receptors, such as opioid, cannabinoid and peptide YY receptors. New research is needed into determining the extent of corticosteroid use. The emetic potential of a range of newer cytotoxics particularly when used in combinations and different scheduling, such as prolonged oral dosing of cytotoxics and use of targeted therapies, are all areas in need of research. More antiemetic studies are needed in niche areas such as in patients receiving high dose chemotherapy, radiation therapy or combined modality therapy. Further evidence of the efficacy of newer antiemetic agents is required in children.

show abstract

“…Currently, in adult patients undergoing highly emetogenic chemotherapy, the administration of a 5-HT 3 receptor antagonist alongside the NK 1 receptor antagonist, aprepitant, and dexamethasone is recommended for the treatment of acute CINV. 10,11 For patients undergoing a moderately emetogenic chemotherapy regimen, palonosetron hydrochloride (Aloxi®, palonosetron; a 5- In paediatric patients, at the time of study design, Multinational Association of Supportive Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO) guidelines recommended prophylactic antiemetic therapy comprising a 5-HT 3 receptor antagonist and dexamethasone to prevent acute CINV in patients scheduled to receive moderately or highly emetogenic chemotherapy. 2 In later guidance, the Pediatric Oncology Group of Ontario (POGO) Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients recommended that children scheduled to receive highly emetogenic therapy should receive antiemetic prophylactic therapy of ondansetron or granisetron plus dexamethasone and aprepitant (≥12 years of age and receiving antineoplastic agents not known to interact with aprepitant) or ondansetron or granisetron plus dexamethasone (<12 years of age or receiving aprepitant interacting agents).…”

Section: Introductionmentioning

confidence: 99%

Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study

Kovács

Wachtel

Basharova

et al. 2016

The Lancet Oncology

View full text Add to dashboard Cite

show abstract

Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations

Cited by 167 publications

References 29 publications

Cyclophosphamide Administration Routine in Autoimmune Rheumatic Diseases: A Review

Cyclophosphamide Administration Routine in Autoimmune Rheumatic Diseases: A Review

Antiemetic research: future directions

Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study

Contact Info

Product

Resources

About